atezolizumab
roche
['biomarker', 'impower,10', 'lung', 'nsclc', 'imp010', 'ca,022,i', 'impower010', 'sclc', 'thoracic', 'atezo', 'tecentriq', 'gi ', 'genentech', 'roche,(-broche),(-rocheter)', 'shanghai,cell,therapy,group', 'natera', 'marker ']
nice update on ctdna in imp010 from #esmoimmuno22 by dr. . atezolizumab is our fda approved adjuvant option for resected stage ii/iii nsclc with pdl1 1% ( 50% for ema). here, we see more granularity on significance of detectable ctdna post-surgery. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Host Official @IASLC Podcast #LCSM #HereWeGo #ITYSL